Search - tctmd.com

Displaying 441 - 460 of 6832

Sort: Relevancy | Date

Presentation NY Valves 2025

Late Health Status Outcomes with Patient-Prosthesis Mismatch After AVR in the PARTNER Trials

Presenter: Yasser M. Sammour

June 25, 2025

Presentation NY Valves 2025

CT Determinants of TAVR Risk: When Should I Treat with TAVR and When Should I Avoid?

Presenter: Hasan Jilaihawi

June 25, 2025

Presentation NY Valves 2025

Anatomic Considerations for Device Selection: Are Device v Device Trials Meaningful?

Presenter: Ole De Backer

June 25, 2025

Presentation NY Valves 2025

Low Flow Low Gradient Severe Aortic Stenosis: How Low Is Too Low To Treat?

Presenter: Matthew John Czarny

June 25, 2025

Presentation NY Valves 2025

Is There Hope for Medical Management of Aortic Stenosis? New Potential Therapies for Prevention and Treatment

Presenter: Brian R. Lindman

June 25, 2025

Presentation NY Valves 2025

Cardiac Damage and Its Impact on Timing of TAVR

Presenter: Philippe Genereux

June 25, 2025

Presentation NY Valves 2025

SIEGEL TAVR: FIH 1 year & US Early Feasibility 30 Day Results

Presenter: Pradeep K. Yadav

June 25, 2025

Presentation NY Valves 2025

Addressing Undertreatment And Disparities In Valvular Heart Disease: Have We Made Progress?

Presenter: Wayne Batchelor

June 25, 2025

Presentation NY Valves 2025

Latest Clinical Insights: Bridging Evidence and Practice

Presenter: Samir R. Kapadia

June 25, 2025

Presentation NY Valves 2025

Optimizing TAVR in Bicuspid Patients with DASI

Presenter: Hasan Jilaihawi

June 25, 2025

Presentation NY Valves 2025

Efficacy of CEP Devices to Reduce Stroke during TAVR: Insights From the TVT Registry

Presenter: David J. Cohen

June 25, 2025

Presentation NY Valves 2025

Mitigating Stroke Risk in TAVR: Global Burden and the Role of Embolic Protection

Presenter: Suzanne J. Baron

June 25, 2025

Presentation NY Valves 2025

Simplified UNICORN for High-risk Valve-in-Valve TAVR

Presenter: Raviteja Reddy Guddeti

June 25, 2025

Presentation NY Valves 2025

Advantages of Splitting Bicuspid Aortic Valve Leaflets Prior to TAVR: A New Paradigm for Leaflet Modification in BAV?

Presenter: Hasan Jilaihawi

June 25, 2025

Presentation NY Valves 2025

TAVR Reintervention Strategies: Unveiling Trends and Outcomes of Redo TAVR and TAVR Explant

Presenter: Shinichi Fukuhara

June 25, 2025

Presentation NY Valves 2025

Repeat Interventions Following Transcatheter Aortic Valve Replacement: A Comparative Analysis of Redo TAVR and Surgical Explantation

Presenter: Chloe Kharsa

June 25, 2025

Presentation NY Valves 2025

High Risk Coronary Obstruction TAVR in SAVR

Presenter: Itsik Ben-Dor

June 25, 2025

Presentation NY Valves 2025

Valve-in-Valve TAVR Using the Navitor Transcatheter Heart Valve

Presenter: Dustin Kliner

June 25, 2025

Presentation NY Valves 2025

"Bi-Unicorn" ViViV TAVR

Presenter: Obrad Kokanovic

June 25, 2025

Presentation NY Valves 2025

Guideline Directed Indications and Consequences of Delayed AVR in Patients With Asymptomatic, Severe Aortic Stenosis: Results From the EARLY TAVR Trial

Presenter: Allan Schwartz

June 25, 2025

Advertisement

Late Health Status Outcomes with Patient-Prosthesis Mismatch After AVR in the PARTNER Trials

CT Determinants of TAVR Risk: When Should I Treat with TAVR and When Should I Avoid?

Anatomic Considerations for Device Selection: Are Device v Device Trials Meaningful?

Low Flow Low Gradient Severe Aortic Stenosis: How Low Is Too Low To Treat?

Is There Hope for Medical Management of Aortic Stenosis? New Potential Therapies for Prevention and Treatment

Cardiac Damage and Its Impact on Timing of TAVR

SIEGEL TAVR: FIH 1 year & US Early Feasibility 30 Day Results

Addressing Undertreatment And Disparities In Valvular Heart Disease: Have We Made Progress?

Latest Clinical Insights: Bridging Evidence and Practice

Optimizing TAVR in Bicuspid Patients with DASI

Efficacy of CEP Devices to Reduce Stroke during TAVR: Insights From the TVT Registry

Mitigating Stroke Risk in TAVR: Global Burden and the Role of Embolic Protection

Simplified UNICORN for High-risk Valve-in-Valve TAVR

Advantages of Splitting Bicuspid Aortic Valve Leaflets Prior to TAVR: A New Paradigm for Leaflet Modification in BAV?

TAVR Reintervention Strategies: Unveiling Trends and Outcomes of Redo TAVR and TAVR Explant

Repeat Interventions Following Transcatheter Aortic Valve Replacement: A Comparative Analysis of Redo TAVR and Surgical Explantation

High Risk Coronary Obstruction TAVR in SAVR

Valve-in-Valve TAVR Using the Navitor Transcatheter Heart Valve

"Bi-Unicorn" ViViV TAVR

Guideline Directed Indications and Consequences of Delayed AVR in Patients With Asymptomatic, Severe Aortic Stenosis: Results From the EARLY TAVR Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content